Education
About Us
Working with TipRanks
Follow Us
Cingulate Inc (CING)
NASDAQ:CING
CING Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.80 - $20.83
Previous CloseN/A
Volume136.88K
Average Volume (3M)86.09K
Market Cap
$15.15M
Enterprise Value$9.66M
Total Cash (Recent Filing)$1.74M
Total Debt (Recent Filing)$5.78M
Price to Earnings (P/E)―
Beta5.51
Next Earnings
May 07, 2025EPS Estimate
-1.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-16.32
Shares Outstanding3,768,400
10 Day Avg. Volume90,995
30 Day Avg. Volume86,089
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.80
P/FCF Ratio0.00
Enterprise Value/Market Cap0.64
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.62
Forecast
1Y Price Target
$13.33Price Target Upside231.59% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
Cingulate Inc News
PremiumCompany Announcements
Cingulate Inc Secures $3M Grant for Anxiety Drug
PremiumCompany Announcements
Cingulate Inc. Reports 2024 Financial and Development Milestones
---
Bulls Say, Bears Say
Bulls Say
Market OpportunityConsidering the ongoing stimulant shortages, especially for generic stimulant products, and that CTx-1301 only requires one dose, daily, the commercial opportunity for Cingulate is attractive.
Product EfficacyCTx-1301 demonstrated a potential best-in-class onset and duration for ADHD, making it a competitive differentiator amidst ongoing stimulant shortages.
Regulatory ProgressCingulate has completed its final FDA-required clinical program for CTx-1301, which is a significant step towards FDA approval for the treatment of ADHD.
Bears Say
Clinical Study ResultsDespite achieving clinical meaningfulness, the Phase 3 study did not achieve statistical significance as it was not powered for this objective.
Financial PerformanceCingulate reported a net loss of $6.1M for the fourth quarter and $15.5M for the year, which could be a concern for investors.
Operating ExpensesOperating expenses in the fourth quarter were significantly higher than expected, potentially affecting financial performance.
---
Ownership Overview
63.15% Insiders
0.25% Mutual Funds
0.16% Other Institutional Investors
36.40% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
CING FAQ
What was Cingulate Inc’s price range in the past 12 months?
Cingulate Inc lowest stock price was $1.80 and its highest was $20.83 in the past 12 months.
What is Cingulate Inc’s market cap?
Cingulate Inc’s market cap is $15.15M.
When is Cingulate Inc’s upcoming earnings report date?
Cingulate Inc’s upcoming earnings report date is May 07, 2025 which is in 21 days.
How were Cingulate Inc’s earnings last quarter?
Cingulate Inc released its earnings results on Mar 26, 2025. The company reported -$1.82 earnings per share for the quarter, missing the consensus estimate of -$1.375 by -$0.445.
Is Cingulate Inc overvalued?
According to Wall Street analysts Cingulate Inc’s price is currently Undervalued.
Does Cingulate Inc pay dividends?
Cingulate Inc does not currently pay dividends.
What is Cingulate Inc’s EPS estimate?
Cingulate Inc’s EPS estimate is -1.01.
How many shares outstanding does Cingulate Inc have?
Cingulate Inc has 3,768,400 shares outstanding.
What happened to Cingulate Inc’s price movement after its last earnings report?
Cingulate Inc reported an EPS of -$1.82 in its last earnings report, missing expectations of -$1.375. Following the earnings report the stock price went up 5.072%.
Which hedge fund is a major shareholder of Cingulate Inc?
Among the largest hedge funds holding Cingulate Inc’s share is GoalVest Advisory LLC. It holds Cingulate Inc’s shares valued at 0.
---
Company Description
Cingulate Inc
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.
---
CING Stock 12 Month Forecast
Average Price Target
$13.33
▲(231.59% Upside)
Technical Analysis
Best Analysts Covering CING
1 Year
1 Year Success Rate
2/7 ratings generated profit
1 Year Average Return
-53.79%
reiterated a buy rating 6 days ago
Copying Boobalan Pachaiyappan's trades and holding each position for 1 Year would result in 28.57% of your transactions generating a profit, with an average return of -53.79% per trade.
---